Welcome to our dedicated page for Bausch & Lomb SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bausch & Lomb's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bausch & Lomb's regulatory disclosures and financial reporting.
Bausch & Lomb Corp director Andrew C. Von Eschenbach reported two open-market sales of common shares. On August 6, 2026, he sold 12,500 shares at a weighted average price of $16.50, with individual trades ranging from $16.43 to $16.54. On August 7, 2026, he sold 6,059 shares at a weighted average price of $16.58, with trades from $16.57 to $16.60. A footnote also states that 4,364 matching restricted share units were forfeited to the issuer for no consideration in connection with his resignation from the board on August 5, 2026.
A shareholder of the company with symbol BLCO has filed to sell 52,900 shares of common stock through Fidelity Brokerage Services LLC. The proposed transaction has an aggregate value of $887,885.14 and is referenced for trading on the NYSE as of 08/10/2026.
The shares relate to multiple Restricted Stock Vesting events classified as compensation, with vesting dates between 07/25/2023 and 05/05/2026, indicating that the stock to be sold was largely acquired through equity compensation awards.
A shareholder of Bausch Lomb Corporation plans to sell 12,500 common shares, with an aggregate market value of $206,192.77. The shares are listed on the NYSE, with 357,165,246 common shares reported outstanding as of August 7, 2026.
The filing notes prior acquisitions of these shares through open market purchases for cash, including 1,695 shares on May 2, 2025 and 4,364 shares on February 27, 2026.
Stewart Andrew J. reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp reported that President, GPIC Andrew J. Stewart received an equity award tied to performance. On August 5, 2026, 16,778 common shares underlying previously granted performance stock units were earned at the 100% target level. These PSUs will vest on February 28, 2027, generally conditioned on continued employment, bringing his direct holdings to 103,211 shares.
Munsch Frederick reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp SVP, Controller and CAO Frederick Munsch reported an equity award tied to 9,091 common shares at a stated price of $0.00 per share, reflecting performance stock units that met 100% of target conditions as of August 5, 2026. These earned PSUs are scheduled to vest on February 28, 2027, subject to continued employment, bringing his directly held common shares to 98,731.
Bausch & Lomb Corp executive Yehia Hashad, EVP of R&D and CMO, reported an acquisition of 20,973 Common Shares at a stated price of $0.00 per share. According to the footnote, these represent common shares underlying performance stock units granted on February 28, 2024 that achieved the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, generally subject to his continued employment, bringing his direct holdings to 187,350 shares. The Rule 10b5-1 trading plan checkbox was not marked.
Bausch & Lomb EVP and CFO Sam Eldessouky reported an award of 50,335 common shares at $0.00 per share, representing shares underlying performance stock units granted on February 28, 2024. After this acquisition he directly holds 393,527 common shares. The earned PSUs will vest on February 28, 2027, subject to his continued employment.
Bausch & Lomb executive Luc Bonnefoy, President, Surgical, reported acquiring 16,778 common shares linked to performance stock units under the 2022 Omnibus Incentive Plan. The PSUs achieved their 100% target performance level as of August 5, 2026 and will vest on February 28, 2027, subject to continued employment. Following this award, Bonnefoy holds 103,801 common shares directly.
Robert D. Bailey, EVP & Chief Legal Officer of Bausch & Lomb Corp, reported a grant/award acquisition of 33,557 common shares underlying performance stock units that earned at 100% of target as of August 5, 2026. These PSUs will vest on February 28, 2027, increasing his direct holdings to 264,241 shares, subject to continued employment.
Bausch & Lomb Corp Chairman and CEO Brent L. Saunders reported two equity-related transactions dated August 5, 2026. The company withheld 4,231 common shares at $16.76 per share to satisfy tax withholding obligations upon vesting of restricted share units. Saunders was also credited with 281,879 common shares underlying performance stock units originally granted on February 28, 2024 that achieved the 100% target performance level as of August 5, 2026; these earned PSUs are scheduled to vest on February 28, 2027, subject to his continued employment. These transactions were not reported as made under a Rule 10b5-1 trading plan.